MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

26.18 +0.04 (+0.15%)
Official Closing Price Updated: 7:00 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Pfizer Earnings: What To Look For From PFE
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors should know. Pfizer beat analys... 
Via StockStory
News headline image
Pfizer Stock: Still Priced Like It's Dead Money ↗
Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Oversold Stock Ready to Bounce Back and 2 We Find Risky
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a co... 
Via StockStory
Topics Artificial Intelligence
News headline image
Pfizer Just Scored a Win That Wall Street Can't Ignore ↗
The pharmaceutical giant just extended the lifespan of one of its top drugs. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗
This particular player has seen its yield rise in recent years. 
Via The Motley Fool
News headline image
Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study ↗
Pfizer reports Phase 3 data showing ELREXFIO improved progression-free survival versus standard therapy in multiple myeloma study. 
Via Benzinga
News headline image
Do Wall Street Analysts Like Bristol-Myers Squibb Stock?
Although Bristol-Myers Squibb has lagged behind the SPX over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects. 
Via Barchart.com
Topics ETFs
News headline image
Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma
From Pfizer Inc.
Via Business Wire
News headline image
2 High-Yielding Dividend Stocks to Buy for Passive Income in April ↗
It's still time to pick up their shares on the dip. 
Via The Motley Fool
Topics Economy Intellectual Property
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗
Via Chartmill
News headline image
Should You Buy, Sell, or Hold Pfizer at $27? ↗
The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question mark. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Reaches Three Settlement Agreements for VYNDAMAX
From Pfizer Inc.
Via Business Wire
News headline image
Are Wall Street Analysts Bullish on Pfizer Stock?
Pfizer has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects. 
Via Barchart.com
Topics ETFs Intellectual Property
News headline image
Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal ↗
Today, April 27, 2026, a jumbo all-cash buyout and merger-arb dynamics put Organon in focus. 
Via The Motley Fool
Topics Stocks
News headline image
Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗
This pharma stock is cheap for a reason. 
Via The Motley Fool
Topics Intellectual Property
News headline image
VCIT vs. IEI Comes Down to What Job Your Bond Sleeve Is Doing ↗
Explore how differences in bond type, risk, and income potential set these two popular ETFs apart for investors. 
Via The Motley Fool
Topics Bonds ETFs
News headline image
Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗
The weight loss drug market may reach almost $100 billion in a few years. 
Via The Motley Fool
News headline image
Is Pfizer's 6% Dividend Yield Safe? Here's What Investors Need to Know. ↗
Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out. 
Via The Motley Fool
Topics Earnings
These S&P500 stocks are the most active in today's session ↗
Via Chartmill
News headline image
Unusual Put Activity Is Flagging a Smart Trade Setup in This New Quantum Computing Stock
Quantum computing firm Infleqtion led Thursday with a 133.59 Vol/OI ratio. The Jan. 15/2027 $10 put made up 23% of volume, which was 2.8 times its 30-day average, making the trade sneaky smart. Here’s... 
Via Barchart.com
Topics Artificial Intelligence Initial Public Offering
News headline image
Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story.
A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside. 
Via Barchart.com
News headline image
Pfizer Declares Second-Quarter 2026 Dividend
From Pfizer Inc.
Via Business Wire
News headline image
Should You Forget Pfizer and Buy This Pharma Stock Instead? ↗
Pfizer's shares have rebounded, but is AbbVie still a better buy among pharmaceutical stocks? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Why Merck (MRK) Shares Are Trading Lower Today
What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a... 
Via StockStory
Topics Government Intellectual Property
News headline image
Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
From Pfizer Inc.
Via Business Wire
News headline image
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗
There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option. 
Via The Motley Fool
News headline image
This Drug Stock Has Crushed the S&P 500 Over the Last Decade ↗
Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Where Will Pfizer Stock Be in 3 Years? ↗
The healthcare giant has been investing heavily in its future growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Better Long-Term Buy: Eli Lilly or Viking Therapeutics? ↗
One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Value Stocks to Research Further and 1 Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story